Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by new investor Northpond Ventures and fueled by existing investors including ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital, and Applied Ventures.
“We are delighted to receive the backing of Northpond Ventures in addition to our existing investors as we advance the field of multiplex biomarker detection and analysis for tissue phenotyping,” said Michael Natan, CEO of Ultivue. “This latest round of financing sets the stage for substantial growth and allows us to continue developing the innovation to meet the evolving needs of our customers in translational and clinical research.”
“The fast market adoption of Ultivue’s reagents and services is making an impact in the field of immuno-oncology research and we are excited to work together with the current investors to drive forward the mission of tissue-based spatial phenotyping,” said Sharon Kedar, Co-Founder, Partner at Northpond Ventures.
About Ultivue
Multiplexed biomarker assays in tissue for research in personalized medicine and digital pathology.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution, while fitting completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper™ assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper™ assay product portfolio and menu of contract research services to provide a comprehensive set of personalized medicine solutions for oncology research as well as other therapeutic areas.
Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190627005059/en/
Source: Ultivue
View this news release online at:
http://www.businesswire.com/news/home/20190627005059/en
